SEC Form 4 · accession 0001209191-18-017175

MAGELLAN HEALTH INC · MGLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO, Magellan Rx Management

Period of report

Mar 5, 2018

Accepted (ET)

Mar 6, 2018 · 3:21 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000019411

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Common Stock, $0.01 par value	Mar 5, 2018	X	1,480	$63.95	A	1,480	D
Ordinary Common Stock, $0.01 par value	Mar 5, 2018	X	7,307	$64.87	A	8,787	D
Ordinary Common Stock, $0.01 par value	Mar 5, 2018	X	6,641	$68.50	A	15,428	D
Ordinary Common Stock, $0.01 par value^F2	Mar 5, 2018	S	15,428	$99.0386	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4,F3	$63.95	Mar 5, 2018	X	1,480	D	—	Mar 3, 2025	Common Stock	1,480	0	D
Stock Option (right to buy)^F4,F5	$64.87	Mar 5, 2018	X	7,307	D	—	Mar 3, 2026	Common Stock	7,307	7,306	D
Stock Option (right to buy)^F4,F6	$68.50	Mar 5, 2018	X	6,641	D	—	Mar 3, 2027	Common Stock	6,641	13,282	D

F1This transaction was effectuated pursuant to a Rule 10b-5-1 Plan.
F2The number of securities reported represents an aggregate number of shares sold in multiple open market transactions at prices ranging from $98.30 to $101.05, inclusive. The price reported represents the weighted average price. The Reporting Person undertakes to provide staff of the SEC, the issuer, or a stockholder of the issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3All of the stock options in this tranche have vested in full.
F4Not applicable.
F5The remainder of 7,306 options shall vest on March 3, 2019.
F6The remainder of 13,282 options shall vest in equal increments on March 3, 2019 and 2020.